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ABSTRACT
Objectives To assess the safety of intra-articular (IA)
autologous tolerogenic dendritic cells (tolDC) in patients
with inflammatory arthritis and an inflamed knee; to
assess the feasibility and acceptability of the approach
and to assess potential effects on local and systemic
disease activities.
Methods An unblinded, randomised, controlled, dose
escalation Phase I trial. TolDC were differentiated from
CD14+ monocytes and loaded with autologous synovial
fluid as a source of autoantigens. Cohorts of three
participants received 1×106, 3×106 or 10×106 tolDC
arthroscopically following saline irrigation of an inflamed
(target) knee. Control participants received saline
irrigation only. Primary outcome was flare of disease in
the target knee within 5 days of treatment. Feasibility
was assessed by successful tolDC manufacture and
acceptability via patient questionnaire. Potential effects
on disease activity were assessed by arthroscopic
synovitis score, disease activity score (DAS)28 and Health
Assessment Questionnaire (HAQ). Immunomodulatory
effects were sought in peripheral blood.
Results There were no target knee flares within 5 days
of treatment. At day 14, arthroscopic synovitis was
present in all participants except for one who received
10×106 tolDC; a further participant in this cohort
declined day 14 arthroscopy because symptoms had
remitted; both remained stable throughout 91 days of
observation. There were no trends in DAS28 or HAQ
score or consistent immunomodulatory effects in
peripheral blood. 9 of 10 manufactured products met
quality control release criteria; acceptability of the
protocol by participants was high.
Conclusion IA tolDC therapy appears safe, feasible
and acceptable. Knee symptoms stabilised in two
patients who received 10×106 tolDC but no systemic
clinical or immunomodulatory effects were detectable.
Trial registration number NCT01352858.
INTRODUCTION
Despite major therapeutic advances, there is no
cure for rheumatoid arthritis (RA) and only a small
proportion of patients achieve drug-free remission,
which is often transient.1 For the remainder, the
need for chronic medications with associated side
effects, sometimes serious, impacts on overall qual-
ity of life. The ideal management of RA is a
therapy that returns the immune system to a state
of self-tolerance, reversing autoimmunity without
requiring long-term treatment.
Dendritic cells (DCs) orchestrate immune
responses, by ingesting and presenting antigens to
T cells.2 3 In health they direct immune attacks
against pathogens and tumours and, in a distinct
state of differentiation, play an important role in
maintaining self-tolerance.4 5 In contrast, in auto-
immunity DCs drive activation and differentiation
of autoreactive effector T cells.6 If this inappropri-
ate activation could be reversed and immune regu-
lation restored, self-tolerance should re-emerge.
Over the past 10 years, we have developed a
method to differentiate human tolerogenic DC
(tolDC) from the blood of healthy individuals and
patients with inflammatory arthritis.7–10 Unlike con-
ventional mature DCs, which produce interleukin
(IL)-12p70 and other proinflammatory cytokines,
tolDC produce no IL-12p70 but high levels of
IL-10. They deviate naïve T cells towards an
IL-10-producing phenotype and induce hypore-
sponsiveness in memory T cells. Importantly, in
mixed cultures they dominate mature, proinflamma-
tory DCs and downregulate T-cell activation. Their
phenotype is stable in the presence of proinflamma-
tory stimuli. Equivalent murine tolDC switch off
collagen-induced arthritis (CIA), with immune
deviation from IL-17 to IL-10 production by CD4+
T cells and a reduction in type II collagen-specific
T-cell responses.11 While our data implicate IL-10
as a key anti-inflammatory cytokine, it can also
boost B-cell responses with pro-immune effects.12
We now report the results of a Phase I trial of
autologous tolDC in patients with rheumatoid and
inflammatory arthritis. This is only the second
reported trial of tolDC in inflammatory arthritis13
and the first to use an intra-articular (IA) route of
administration, chosen to optimise the detection
and management of potential AEs.
METHODS
TolDC manufacture
We previously reported our method for manufac-
turing therapeutic grade tolDC investigational
medical product (IMP).9 Our full good manufactur-
ing practice (GMP) protocol is provided in the
online supplementary methods. TolDC were loaded
with autologous synovial fluid (SF) as a source of
relevant autoantigens,14–16 enabling the treatment
of both patients with seropositive RA and patients
with seronegative RA, as well as other arthritides.
Prior to administration, tolDC satisfied all quality
control (QC) release criteria (table 1).
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Participants
Participants, aged 18 or over, had inflammatory arthritis of at
least 6 months’ duration, including an inflamed knee joint with
an effusion and at least 30 min early morning stiffness. They
had failed at least one disease-modifying antirheumatic drug
(DMARD), including current therapy. TolDC was added to
stable DMARD and anti-inflammatory therapies. Intramuscular
glucocorticoids and IA injections of the target knee were not
permitted for 6 weeks prior to baseline. Standard exclusion cri-
teria were applied (see online supplementary table S1).
Study design
This was an unblinded, randomised, controlled, dose escalation
Phase I trial of IA tolDC administered into an inflamed knee joint
(the target knee). The trial protocol, available at http://
clinicaltrials.gov/ct2/show/NCT01352858, was approved by the
Medicines and Healthcare Products Regulatory Agency and by
the National Research Ethics Service Committee North East
(Sunderland) (EudraCT number: 2011-001582-41). The trial
was conducted according to the International Council for
Harmonisation of Technical Requirements for Pharmaceuticals
for Human Use Good Clinical Practice (ICH GCP) and the
Declaration of Helsinki. There were three dosing cohorts of
1×106, 3×106 and 10×106 viable tolDC administered via a
single arthroscopic injection following saline irrigation. Each
cohort comprised four participants, randomly allocated to tolDC
(n=3) or control intervention of target knee arthroscopic saline
irrigation only (n=1). The decision to dose escalate between
cohorts was decided by an independent data-monitoring commit-
tee based on safety and tolerability data, recorded 5 days after
treatment of the last participant in each cohort.
The study design is outlined in figure 1. Following informed
consent on day −14, an infectious disease screen was performed
and SF aspirated for use during tolDC manufacture. Participants
returned on day −7 for leucapheresis. At the baseline visit (day
0), the target joint was arthroscopically irrigated followed by
tolDC administration. IA administration was chosen to provide
an early and robust signal of disease deterioration and the
opportunity for joint irrigation under those circumstances.
Primary outcome
The primary objective of Autologous Tolerogenic Dendritic
Cells for Rheumatoid and Inflammatory Arthritis (AuToDeCRA)
was to assess safety of the intervention. Participants were ques-
tioned about symptomatic deterioration by telephone on days
1–5, with particular focus on the target knee. If deterioration
was reported on two successive days, participants were assessed
in person. If deterioration was confirmed, a further arthroscopic
examination was performed with irrigation and IA glucocorti-
coid if indicated. If infection was suspected, this was managed
appropriately. Knee assessment tools standardised subjective and
objective assessments (see online supplementary figures S1 and
S2). Routine safety assessments took place on days 7 and 14.
The latter included a further arthroscopic examination and, if
synovitis persisted, an arthroscopic IA glucocorticoid injection
was administered. The final study visit on day 91 was identical
to day 14, except arthroscopy was only indicated if patients had
not previously received IA glucocorticoid during the study.
The primary outcome was the proportion of participants
experiencing a target knee flare within 5 days of tolDC adminis-
tration and, additionally, the proportion experiencing serious
AEs (SAEs) and AEs throughout the trial. Although tolDC were
stable in vitro, a significant concern was their potential to
become activated in an inflamed environment—our experiments
in murine CIA demonstrated worsening of joint inflammation
when antigen-loaded mature DCs were administered.11 Knee
flares beyond 5 days were deemed more likely to represent
inflammation returning post-irrigation, whereas, if tolDC were
efficacious, we predicted prolonged symptomatic benefit.
Secondary and exploratory outcomes
Secondary objectives were to assess feasibility and tolerability.
Feasibility was defined by the proportion of participants
Table 1 Summary of QC release criteria data
Purity Phenotype Functionality
Patient Dose
Viability
(%)*
CD11c
(%)‡
HLA-DR
(%)‡
CD83
(MFI)§
CD86
(MFI)¶
TLR2
(MFI)**
IL-10 (pg/
mL)††
IL-12 (pg/
mL)‡‡ Sterility†
QC
result
1 1×106 88 100 100 58 462 1434 2364 <50 Pass Pass
2 Placebo – – – – – – – – – –
3 1×106 88 99.9 100 41 773 1188 3373 <50 Pass Pass
4 1×106 90 100 100 109 356 758 10 510 <50 Pass Pass
5 3×106 90 99.9 100 173 384 2085 2295 <50 Pass Pass
6 Placebo – – – – – – – – – –
7 3×106 96 100 99.9 73 390 2921 5164 <50 Pass Pass
8 3×106 96 100 100 61 1878 251 1331 <50 Pass Fail
9 3×106 71 100 100 70 772 926 2040 <50 Pass Pass
10 10×106 80 100 100 83 264 4276 2425 <50 Pass Pass
11 Placebo – – – – – – – – – –
12 10×106 79 100 100 62 464 1704 4679 <50 Pass Pass
13 10×106 95 99.8 100 135 320 1473 1607 <50 Pass Pass
*Viability was determined using trypan blue exclusion and expressed as percentage of total cells. To pass quality control (QC) viability had to be >70%.
†Sterility was assessed by BacT/Alert and fungal screen on day 0, day 3 and final product (day 7). To pass QC, the product had to pass sterility screening with no organisms detected.
‡CD11c and human leucocyte antigen—antigen D-related (HLA-DR) expression determined using flow cytometry and expressed as a percentage of viable cells. To pass QC, the percentage
of positive cells had to be >90% for both markers.
§CD83 expression determined using flow cytometry and expressed as a median fluorescence intensity (MFI) of viable cells. To pass QC, CD83 MFI had to be <350.
¶CD86 expression determined using flow cytometry and expressed as a MFI of viable cells. To pass QC, CD86 MFI had to be <1500.
**Toll-like receptor (TLR)2 expression determined using flow cytometry and expressed as a MFI of viable cells. For information only. Positive result=TLR2 MFI >200.
††Interleukin (IL)-10 levels in supernatant from the 7 days culture were determined by ELISA. To pass QC, IL-10 levels had to be >1000 pg/mL.
‡‡IL-12 levels in supernatant from the 7 days culture were determined by ELISA. To pass QC, IL-12 levels had to be <50 pg/mL.
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entering the study from whom tolDC could be prepared (the
success rate of tolDC manufacture). Tolerability was scored as
the proportion of participants who rated the study and its com-
ponents as partly or completely acceptable, assessed via a ques-
tionnaire administered at the final study visit (see online
supplementary figure S3).
Exploratory objectives included assessment of the potential
effects of tolDC on local and systemic disease activities.
Exploratory outcomes included arthroscopic assessment of
target knee synovitis (days 0 and +14); disease activity score
(DAS)28 and Health Assessment Questionnaire (HAQ) at each
study visit; peripheral blood T-cell phenotype assessed by intra-
cellular cytokine staining and peripheral blood cytokine levels
(days 0, 14 and 91, see online supplementary methods).
Arthroscopy was performed by an unblinded investigator using
a published method.17
Statistics
This Phase I trial was not powered for comparative hypothesis
testing and basic descriptive statistics are used to summarise
outcome data, demographic and operational information.
RESULTS
Participants
Sixteen participants were screened. SF could not be obtained
from three and the cell product did not meet release criteria in
participant 8 (see below). Of the remaining 12 participants, 6
had seropositive RA, 1 had seronegative RA, 3 had psoriatic
arthritis and 2 had undifferentiated seronegative arthritis
(table 2). The 10×106 tolDC cohort contained only one patient
with RA, whereas the lower dose cohorts contained three each.
Disease duration ranged from 2 to 43 years and DAS28 ranged
from 1.4 to 6.0. Background DMARD therapy ranged from nil
to biological therapy.
Product characteristics
Table 1 provides the QC release criteria for tolDC, encompass-
ing viability, sterility, phenotype and function. The IMP gener-
ated from cells of participant 8 had higher cell surface CD86
expression than specified in our release criteria and therefore
could not be released as part of the clinical trial. All other
release criteria were met and, following informed discussion,
the participant elected to receive the product but their data are
reported separately. Toll-like receptor 2 is upregulated during
tolDC differentiation and, while recorded in table 1, did not
constitute a release criterion. Online supplementary figure S4
exemplifies flow cytometry QC data.
Primary outcome and AEs
No participants developed worsening symptoms in the target
knee during days 1–5. There were two SAEs, both in participant
3 with highly active, refractory RA (table 3). A generalised RA
flare occurred on day 70, requiring hospitalisation. Adalimumab
was switched to tocilizumab but the participant was re-admitted
Figure 1 Overview showing tolerogenic dendritic cells (tolDC) treatment protocol. Following informed consent on day −14, an infectious disease
screen was performed and synovial fluid (SF) aspirated under ultrasound guidance for use during tolDC manufacture. Participants returned 7 days
later (day −7) for leucapheresis, their leucapheresis product being transferred to the good manufacturing practice facility for initiation of tolDC
manufacture. After a further 7 days participants returned (day 0, baseline visit) and, following a clinical assessment and ultrasound assessment of
the target knee, underwent fibre-optic arthroscopy. The target knee joint was irrigated with 1 L of normal saline, following which tolDC were
administered arthroscopically. On days 7 and 14 participants returned for safety assessments. The day 14 visit also entailed an arthroscopic
assessment of the target knee. If the participant remained symptomatic and/or the knee remained inflamed an arthroscopic intra-articular
glucocorticoid injection was administered. The final study visit on day 91 was identical to the day +14 visit.
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15 days later with pneumonia requiring IV antibiotics. Both
events were felt unlikely to be related to tolDC.
37 AEs were recorded (table 3). 15 were felt possibly related
to therapy, largely because of their timing. Despite the lack of
protocol-defined target knee flares, there were three episodes of
target knee synovitis requiring treatment, noted on days 7 (par-
ticipant 9) and 10 (participants 1 and 5). Participant 9 also had
contralateral knee synovitis, present since baseline. In addition
participant 3, who was hospitalised with an RA flare on day 70,
also suffered a flare on day 9. Two of these AEs occurred in the
1×106 tolDC and two in the 3×106 tolDC cohort. Participant
7 reported increased target knee stiffness on day 9 and partici-
pant 13 reported generalised stiffness and discomfort on day 23
but, clinically, these were not disease flares. Participant 13 subse-
quently developed non-target knee synovitis on day 84. Two
episodes of rhinorrhoea (3×106 tolDC and control), two epi-
sodes of upper respiratory tract infection (10×106 tolDC and
control) and folliculitis (10×106 tolDC) were the only infec-
tious AEs, excluding wound infections (see below). Two partici-
pants with psoriatic arthritis reported minor worsening of
psoriasis on days 6 and 62. There were two reports of self-
resolving knee pain, one provoked by exercise.
Twelve AEs were possibly, probably or definitely attributable
to procedures, including two wound infections (one in partici-
pant 8 whose product failed QC) and a fluid leak, an episode of
citrate toxicity related to leucapheresis and a vasovagal episode
related to arthroscopy. Self-resolving AEs occurring within 24 h
of tolDC administration, such as fatigue or target knee pain or
stiffness, were attributed to the procedure rather than to tolDC.
All AEs were assessed as mild or moderate with no evidence of
a dose–response relationship. In particular knee, or systemic
disease, flares only occurred in lower dose cohorts, apart from a
late (day 84) non-target knee flare in participant 13.
Secondary outcomes—feasibility and participant acceptability
TolDC that met release criteria were manufactured from 9 of 10
production runs (see above). Participant acceptability was high
(table 4). About 91% of participants rated the study overall as
acceptable. Equivalent percentages were 88%, 75%, 91% and
64% for leucapheresis, knee aspiration, ultrasound and arthro-
scopy. About 91% found participation convenient and 90%
would participate again.
Potential efficacy
Figure 2 illustrates the exploratory outcome of arthroscopic
assessment of target knee synovitis on day 0 and day 14. A 0–4
scale was used to estimate synovial hypertrophy, vascularity and
synovitis. One participant in the 10×106 tolDC cohort declined
day 14 arthroscopy. There was no evidence for change in syno-
vial hypertrophy with tolDC, improvement being noted in only
one control participant. Two of three participants receiving
3×106 tolDC and one of two assessable participants receiving
10×106 tolDC demonstrated improvement in vascularity on day
14, whereas no improvement was seen in six participants receiv-
ing 1×106 tolDC or control intervention. Synovitis improved in
one of three participants in each of the 1×106 and 3×106
tolDC cohorts and in both assessable patients in the 10×106
tolDC cohorts, but zero of three controls. Notably there was no
worsening of any arthroscopic parameter at day 14 in the
10×106 tolDC cohort. Furthermore, although most patients did
not report target knee flares, 10 participants received IA gluco-
corticoid at day 14 for arthroscopically evident synovitis. The
exceptions were two participants in the 10×106 tolDC cohort,
one of whom declined day 14 arthroscopy due to symptom
resolution (participant 10) and the other, participant 12, had
near complete resolution of synovitis at arthroscopy. Both
remained asymptomatic and declined day 91 arthroscopies.
Interestingly, participant 8, whose cells failed release criteria,
also did not require IA glucocorticoid on day 14; day 91 arthro-
scopy revealed stable hypertrophy and vascularity but mild wor-
sening of synovitis. There was no consistent trend in DAS28 or
HAQ scores across the dosing cohorts (data not shown), nor in
peripheral blood T-cell phenotype or serum cytokine levels (see
online supplementary figures S5 and S6).
DISCUSSION
The primary purpose of this unblinded Phase I trial was to
assess the safety of autologous tolDC therapy. We consequently
Table 2 Participant demographics, current and prior treatment and experimental cohort
Participant
number
Age
(years) Diagnosis
Disease duration
(years)
DAS28 at
baseline
Background DMARD
treatment Prior treatments
tolDC
treatment
1 75 Seropositive RA 43 2.6* PEN Nil 1×106
2 59 Seropositive RA 19 4.5 MTX s/c SSZ, po MTX Washout
3 53 Seropositive RA 14 6.0 ADA PEN, gold, SSZ, MTX, LEF,
ETA, ADA, RTX
1×106
4 56 Psoriatic arthritis 6 2.6 MTX, LEF Nil 1×106
5 41 Undifferentiated
seronegative arthritis
3 3.5* MTX SSZ 3×106
6 63 Seropositive RA 31 5.1 MTX, ETA MTX, LEF, gold, SSZ, PEN Washout
7 35 Seropositive RA 3 4.4 MTX, SSZ, HCQ Nil 3×106
8† 47 Seronegative arthritis 1 1.4 MTX SSZ 3×106†
9 60 Seronegative RA 14 5.2 MTX, HCQ Nil 3×106
10 77 Psoriatic arthritis 3 4.4* MTX, SSZ Nil 10×106
11 65 Seropositive RA 2 4.5 MTX, SSZ, HCQ Nil Washout
12 57 Undifferentiated
seronegative arthritis
4 2.3 MTX Nil 10×106
13 45 Psoriatic arthritis 18 2.2 Nil MTX, SSZ 10×106
*Screening DAS28 values.
†Cells failed release criteria.
ADA, adalimumab; DMARD, disease-modifying antirheumatic drug; ETA, etanercept; HCQ, hydroxychloroquine; LEF, leflunomide; MTX, methotrexate; PEN, penicillamine; po, oral
administration; RA, rheumatoid arthritis; RTX, rituximab; s/c, subcutaneous administration; SSZ, sulfasalazine; tolDC, tolerogenic dendritic cells.
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designed our trial to provide a robust signal of worsening syno-
vitis and a means to address this if it occurred. IA administration
served both purposes: a tolDC-induced flare should have caused
a rapid and significant increase in target knee synovitis, in which
case the joint could be irrigated and treated with local glucocorti-
coid. We estimated 5 days as a likely time course, because patho-
genic T cells are enriched in an inflamed joint18–20 and could
potentially be activated if tolDC were unstable. No flare occurred
within this timeframe although four episodes of target knee or
systemic synovitis were recorded between days 7 and 10, in parti-
cipants receiving 1×106 or 3×106 tolDC. Furthermore, at day
14, local glucocorticoid was administered for arthroscopic synovi-
tis in all patients in the 1×106 and 3×106 tolDC cohorts as well
as all three controls. In contrast, two of three participants who
received 10×106 tolDC did not require local glucocorticoid
throughout the study. Therefore, we cannot state unequivocally
Table 3 Adverse events and serious adverse events (SAEs)
Study
number Cohort Adverse event Grade Day Action
Relationship to
treatment
Relationship to
procedure
1 1×106 tolDC Discomfort right heel Mild 0 Nil Unrelated Probable (secondary to
immobilisation)
1 1×106 tolDC Redness right heel Mild 0 Nil Unrelated Probable (secondary to
immobilisation)
1 1×106 tolDC Bruising below knee Mild 1 Nil Unrelated Related to arthroscopy
1 1×106 tolDC Target knee synovitis Moderate 10 Aspiration d10, IA
glucocorticoid d14
Possible Unrelated
1 1×106 tolDC Wound infection target knee Mild 31 Oral flucloxacillin Unlikely Related to arthroscopy
2 Control Leg cramps Mild ≈14 Quinine sulfate Unrelated Unlikely
3 1×106 tolDC Iron deficiency anaemia Moderate −14 Ferrous sulfate Unrelated Unrelated
3 1×106 tolDC Citrate Toxicity Mild −7 Nil Unrelated Related to leucapheresis
3 1×106 tolDC Increased target knee pain Moderate 0 Analgesia Unlikely Related to arthroscopy
3 1×106 tolDC Fatigue Mild 1 Nil Unlikely Possible
3 1×106 tolDC General RA flare Moderate 9 IM glucocorticoid Possible Unrelated
3 1×106 tolDC General RA flare N/A (SAE) 70 Hospitalised, commenced
tocilizumab
Unlikely Unrelated
3 1×106 tolDC Pneumonia N/A (SAE) 85 Hospitalised, antibiotics Unlikely Unrelated
4 1×106 tolDC Increased stiffness of target knee Moderate 1 Nil Unlikely Possible
4 1×106 tolDC New patch of psoriasis on forearm Mild 6 Topical steroid/calcipitriol Possible Unrelated
4 1×106 tolDC Increased pain both knees Mild 6 Nil Possible Unrelated
5 3×106 tolDC Flare IA Mild −7 Nil Unrelated Unrelated
5 3×106 tolDC Rhinorrhoea Mild 3 Nil Possible Unrelated
5 3×106 tolDC Target knee synovitis Moderate 10 Aspirated, naproxen dose ↑ Possible Unrelated
5 3×106 tolDC Eczema right elbow Mild 57 Topical hydrocortisone Unlikely Unrelated
6 Control Rash right forearm Mild −7 Nil Unrelated Unrelated
6 Control Upper respiratory tract infection Mild 44 Oral amoxicillin Unrelated Unrelated
7 3×106 tolDC Increased stiffness in target knee Mild 9 Ibuprofen Possible Unrelated
8* Wound infection Mild 2 Oral flucloxacillin Unrelated Related to arthroscopy
9 3×106 tolDC Non-target knee synovitis Moderate 0 Ibuprofen Unrelated Unrelated
9 3×106 tolDC Fatigue Mild 4 Nil Possible Unrelated
9 3×106 tolDC Elevated C reactive protein and
bilateral knee synovitits
Moderate 7 IA glucocorticoid Possible Unrelated
9 3×106 tolDC Fatigue Mild 10 Nil Possible Unrelated
9 3×106 tolDC Fluid leak from target knee wound Mild 21 Oral flucloxacillin Unrelated Related to arthroscopy
10 10×106 tolDC Increased target knee pain after
long walk
Mild 6 Nil Possible Unrelated
10 10×106 tolDC Worsening psoriasis bottom of feet Mild 55 Topical calcipitriol Possible Unrelated
10 10×106 tolDC Arthralgia due to osteoarthritis Mild ≈60 Nil Unrelated Unrelated
11 Control Iron deficiency anaemia Moderate ≈11 Ferrous gluconate Unlikely Possible
11 Control Rhinorrhoea Mild 13 Nil Unrelated Unrelated
13 10×106 tolDC Vasovagal episode Mild 0 Nil Unrelated Related to arthroscopy
13 10×106 tolDC Upper respiratory tract infection Mild 11 Paracetamol Possible Unrelated
13 10×106 tolDC General stiffness and discomfort Mild 23 Nil Possible Unrelated
13 10×106 tolDC Folliculitis Mild 28 Nil Possible Unrelated
13 10×106 tolDC Swelling non-target knee with
effusion
Mild 84 IA glucocorticoid Unlikely Unrelated
*Cells from study number (participant) 8 did not meet QC release criteria, see table 1.
IA, intra-articular; IM, intra-muscular; N/A, not applicable; RA, rheumatoid arthritis; tolDC, tolerogenic dendritic cells.
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that tolDC therapy is safe but it is possible that most participants
in this small trial received a subtherapeutic dose of tolDC, the
‘flares’ and arthroscopic synovitis on day 14 reflecting the natural
history of synovitis following joint irrigation.
Participant 3, with refractory RA, suffered two SAEs. The first
was a disease flare 10 weeks after tolDC treatment. Adalimumab
was switched to tocilizumab but pneumonia developed 14 days
later. Neither SAE was felt related to tolDC therapy. This parti-
cipant also suffered a generalised RA flare on day +9, suggesting
they had unstable disease. Skin psoriasis was reported as stable
at baseline in patients 4 and 10 and, therefore, minor worsening
on days 6 and 62 was deemed potentially attributable to tolDC.
The only infections recorded were two wound infections related
to arthroscopy ports, two upper respiratory tract infections, two
episodes of rhinorrhoea and one of folliculitis. All AEs were
categorised as mild or moderate, with no dose–response.
Each tolDC product was subject to QC assessment. Purity,
surface phenotype and cytokine production were based on char-
acteristics which we have consistently observed to distinguish
tolDC from mature DCs. Because of a necessarily narrow time
Table 4 Participant acceptability scores
Question N
1. Totally
disagree
2. Partly
Disagree
3. Neither agree nor
disagree
4. Partially
agree
5. Totally
agree
Per cent answer
4 or 5
Per cent
answer 5
Taking part in the study was
convenient
11 1 0 0 2 8 91 73
The overall study was
acceptable
11 1 0 0 1 9 91 82
I would take part in the study
again
10 1 0 0 2 7 90 70
Knee joint aspiration was
acceptable
8 1 0 1 1 5 75 63
Leucapheresis was acceptable 8 1 0 0 1 6 88 75
Knee ultrasound was
acceptable
11 1 0 0 1 9 91 82
Knee arthroscopy was
acceptable
11 1 1 2 3 4 64 36
Figure 2 Arthroscopic synovitis scores are presented. Hypertrophy, vascularity and synovitis were scored on a 0–4 scale (17). (A) Individual patient
data are illustrated for days 0 and 14 (one patient in the 10×106 tolerogenic dendritic cells (tolDC) cohort declined day 14 arthroscopy). (B) Fold
change is shown in hypertrophy, vascularity and synovitis scores compared with day 0. Data are plotted as the mean value for each cohort.
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window following completion of manufacture (approximately
3 h), some data were unavailable at the time of administration.
Sterility of the administered product, and cytokine production,
only became available later (secondary release criteria). Only
one product failed to meet primary release criteria, with CD86
expression modestly above the specified limit. Despite the inten-
sive nature of the protocol, 91% of participants rated their
experience as acceptable. Arthroscopy itself was rated least
favourably, but most participants totally (4/11) or partially (3/
11) rated it as acceptable. About 90% would participate again in
a similar study.
On the basis of this small, unblinded, Phase I trial we believe
that tolDC therapy is safe and worthy of further investigation.
This conclusion is based on the absence of protocol-defined target
knee flares and on anecdotal evidence of improvement in partici-
pants in the highest dose cohort. There were three knee flares
recorded 7–10 days post-tolDC administration but these occurred
in the lower dose cohorts and are therefore more likely to reflect
the natural history of knee synovitis following joint irrigation.
Because there were no prior reports of tolDC administration in
participants with inflammatory arthritis, our dosing regimen was
based on cancer strategies. In those scenarios, however, mature
DCs boost an anti-tumour immune response and extrapolation to
tolerance induction is not necessarily appropriate. Indeed, extra-
polation from our prior work in CIA would have predicted a
higher therapeutic dose. In contrast, in a recently published study
in RA, 1×106 and 5×106 autologous modified DCs loaded with
citrullinated peptide antigens demonstrated possible clinical
benefit and biological activity.13 However, those cells were manu-
factured by exposure to a nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-κB) inhibitor and were administered
intradermally. The IA route, while providing a robust safety
read-out, may provide a more challenging environment for
tolDC to demonstrate efficacy. An important additional question
is whether the IA route could provide a systemic effect. No such
effect was evident in our study, either clinically or in terms of
T-cell modulation. We are currently planning an extension to
AuToDeCRA in which 10×106 tolDC will be radiolabelled
before IA administration. This will address whether IA tolDC
migrate to local lymph nodes, where they could modulate the sys-
temic immune response.
Our protocol enabled treatment of a range of arthritides.
Seven participants had RA, three had psoriatic arthritis and two
had undifferentiated seronegative arthritis. Although psoriatic
arthritis may be considered a disease of the innate immune
system, there remains considerable support for an autoimmune
aetiology.21 Furthermore, some tolDC safety concerns (eg, steri-
lity, potential for proinflammatory cytokine release) are inde-
pendent of the disease being treated. In fact the patients with
possible sustained responses had psoriatic arthritis and seronega-
tive undifferentiated arthritis. This may reflect diagnostic imbal-
ance across dosing cohorts, the only RA patient in the 10×106
tolDC cohort receiving control intervention. Nonetheless, these
data emphasise the safety and potential utility of tolDC across a
range of arthritides with differing aetiology. Notably, targeting
IL-17 is effective in psoriatic arthritis and tolDC deviate T-cells
in CIA from IL-17 to IL-10 production.11
While ideal for assessing safety, and well-tolerated by partici-
pants, IA tolDC administration is an invasive intervention.
TolDC have also been administered intradermally in juvenile
type 1 diabetes22 and intraperitoneally in Crohn’s disease.23
Intradermal administration provides a more convenient route of
administration particularly if, as in our preclinical studies, multi-
ple tolDC administrations are ultimately required for robust
efficacy.11 Similarly, loading tolDC with autologous SF broadens
the target population and obviates the need for tissue-typing,
which is generally necessary when loading tolDC with autoanti-
genic peptides. Nonetheless, joint aspiration is a further invasive
procedure and three participants were excluded because SF
could not be obtained. Thus, there are advantages and disadvan-
tages to our current protocol. Nonetheless, we believe that
AuToDeCRA has defined a safe, and potentially active, dose of
tolDC on which to base future work.
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